SCHEMBL17586392

SCHEMBL17586392

CCCCCCCCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCCCCCCCC)C(=O)CCCCN(C)C

nearest known ligand 0.74

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 5/20 0.74
DGKA P23743 1/20 0.57
KDM5A P29375 4/20 0.48
PRSS1 P07477 1/20 0.47
PRSS2 P07478 1/20 0.47
PRSS3 P35030 1/20 0.47
PAM P19021 2/20 0.45
NAAA Q02083 1/20 0.45
KDM4C Q9H3R0 3/20 0.44
PHF8 Q9UPP1 1/20 0.44
TSHR P16473 1/20 0.43
MAPT P10636 1/20 0.43
KDM5C P41229 1/20 0.42
KDM5B Q9UGL1 1/20 0.42
KDM4A O75164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18350966 0.99 DNM1 (0.72) DNM1DGKAKDM5APRSS1PRSS2
SCHEMBL14157454 0.97 DNM1 (0.74) DNM1DGKAKDM5APRSS1PRSS2
SCHEMBL26054432 0.96 DNM1 (0.72) DNM1DGKAKDM5APRSS1PRSS2
SCHEMBL18335339 0.96 DNM1 (0.72) DNM1DGKAKDM5APRSS1PRSS2
SCHEMBL18350965 0.94 DNM1 (0.74) DNM1DGKAKDM5APRSS1PRSS2
SCHEMBL21027726 0.93 DNM1 (0.64) DNM1DGKAKDM5APRSS1PRSS2
SCHEMBL14157552 0.93 DNM1 (0.77) DNM1DGKAKDM5APRSS1PRSS2
SCHEMBL21026909 0.92 DNM1 (0.63) DNM1DGKAKDM5APRSS1PRSS2
SCHEMBL17586403 0.92 DNM1 (0.63) DNM1DGKAMAPT
SCHEMBL15027024 0.92 DNM1 (0.66) DNM1DGKAKDM5APRSS1PRSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2858974-B9 LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS NITTO DENKO CORP (JP) 2022-07-20 EP disclosed
EP-3489220-B9 LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS NITTO DENKO CORP (JP) 2021-11-10 EP disclosed
EP-3489220-B9 LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS NITTO DENKO CORP (JP) 2021-11-10 EP disclosed
EP-3489220-B1 LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS NITTO DENKO CORP (JP) 2021-08-18 EP disclosed
EP-3489220-B1 LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS NITTO DENKO CORP (JP) 2021-08-18 EP disclosed
US-20200085957-A1 LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS NITTO DENKO CORPORATION (JP) 2020-03-19 US disclosed
US-10441659-B2 Lipids for therapeutic agent delivery formulations NITTO DENKO CORPORATION (JP) 2019-10-15 US disclosed
US-10441659-B2 Lipids for therapeutic agent delivery formulations NITTO DENKO CORPORATION (JP) 2019-10-15 US disclosed
US-20190275158-A1 SKIN FIBROSIS TREATMENT AGENT NITTO DENKO CORP (JP) 2019-09-12 US disclosed
EP-3536343-A1 SKIN FIBROSIS TREATMENT AGENT Nitto Denko Corporation (JP) 2019-09-11 EP disclosed
EP-3489220-A1 LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS Nitto Denko Corporation (JP) 2019-05-29 EP disclosed
EP-3489220-A1 LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS Nitto Denko Corporation (JP) 2019-05-29 EP disclosed
EP-2858974-B1 LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS NITTO DENKO CORP (JP) 2018-10-17 EP disclosed
US-9976142-B2 Targeting molecule and a use thereof NITTO DENKO CORPORATION (JP) 2018-05-22 US disclosed
US-9976142-B2 Targeting molecule and a use thereof NITTO DENKO CORPORATION (JP) 2018-05-22 US disclosed
US-20170022500-A1 A TARGETING MOLECULE AND A USE THEREOF NITTO DENKO CORPORATION (JP) 2017-01-26 US disclosed
US-20170022500-A1 A TARGETING MOLECULE AND A USE THEREOF NITTO DENKO CORPORATION (JP) 2017-01-26 US disclosed
US-9308267-B2 Lipids for therapeutic agent delivery formulations NITTO DENKO CORPORATION (JP) 2016-04-12 US disclosed
US-9308267-B2 Lipids for therapeutic agent delivery formulations NITTO DENKO CORPORATION (JP) 2016-04-12 US disclosed
US-20160074514-A1 Lipids for Therapeutic Agent Delivery Formulations NITTO DENKO CORPORATION (JP) 2016-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170022500-A1 A TARGETING MOLECULE AND A USE THEREOF STRA6, RBP1, FABP1 DNM1 2752/4885DGKA 3550/4885KDM5A 2466/4885
US-20160074514-A1 Lipids for Therapeutic Agent Delivery Formulations LIPA, SGMS2, SGMS1 DNM1 235/4885DGKA 377/4885KDM5A 4875/4885
US-20200085957-A1 LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS LIPA, SGMS2, SGMS1 DNM1 235/4885DGKA 377/4885KDM5A 4875/4885
US-10441659-B2 Lipids for therapeutic agent delivery formulations LIPA, SGMS2, SGMS1 DNM1 235/4885DGKA 377/4885KDM5A 4875/4885
US-20190275158-A1 SKIN FIBROSIS TREATMENT AGENT COL1A1, COLGALT1, COL14A1 DNM1 4615/4885DGKA 901/4885KDM5A 975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.